stockportfolio.pro
Stocks / GLUE vs IMCR
GLUE vs IMCR
Monte Rosa Therapeutics, Inc. and Immunocore Holdings plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Monte Rosa Therapeutics, Inc. (GLUE) | Immunocore Holdings plc (IMCR) | |
|---|---|---|
| Market cap | $1.5B | $1.4B |
| Revenue (latest FY) | $123.67M | $400.02M |
| Net income (latest FY) | $-38.63M | $-35.51M |
| Revenue growth (5y CAGR) | — | 82.0% |
| Net margin | -31.2% | -8.9% |
| Return on equity | -16.6% | -9.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GLUE — free Open IMCR — freeFrequently asked questions
Which is bigger, GLUE or IMCR?
Monte Rosa Therapeutics, Inc. is larger by market capitalization — $1.5B versus $1.4B.
Which grows faster, GLUE or IMCR?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.